Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2016-05-12 Earnings Release
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
STADA Arzneimittel AG: First quarter of 2016 better than expected - reported key earnings figures substantially higher than previous year - very strong development of the German Generics segment
Earnings Release Classification · 100% confidence The document text explicitly details key financial figures (sales, EBITDA, net income, EPS) for the 'First quarter of 2016' compared to Q1/2015. It includes summary tables and management commentary on performance, which is characteristic of an Earnings Release (ER). Although it is a press release disseminated via DGAP, its primary content is the initial announcement of periodical financial results, not a comprehensive report like a 10-K or IR. It is too detailed for just a Report Publication Announcement (RPA) as it contains the actual figures, not just a notice that a report is available. Therefore, it fits the definition of an Earnings Release (ER). Q1 2016
2016-05-12 English
Datum:12.05.2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Zwischenbericht 3 Monate 2016' (Interim Report 3 Months 2016) for STADA Arzneimittel AG. It contains detailed financial tables, segment analysis, and management commentary on the company's performance for the first quarter of 2016. As it provides comprehensive financial statements and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2016
2016-05-12 German
STADA Arzneimittel Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 09.06.2016 in Frankfurt am Main mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is explicitly titled 'Einladung zur ordentlichen Hauptversammlung 2016' (Invitation to the Annual General Meeting 2016) and contains the full agenda (Tagesordnung) for the meeting scheduled for June 9, 2016. It details voting proposals (e.g., dividend approval, discharge of management/supervisory board) and instructions for shareholder participation and proxy voting. This content directly corresponds to the materials distributed to shareholders in preparation for an Annual General Meeting. Therefore, the classification is AGM-R (AGM Information).
2016-04-28 German
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables regarding the 'Acquisition/disposal of shares with voting rights' and the resulting percentage of voting rights held by 'Deutsche Asset Management Investment GmbH' in STADA Arzneimittel AG. This directly corresponds to the definition of a notification regarding changes in significant share ownership levels, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although the header mentions 'Voting Rights Announcements', the content is a specific disclosure of a change in a major holding threshold crossing, which MRQ covers more precisely than the general 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which typically relates to the outcome of a shareholder vote, not an insider/major shareholder transaction disclosure.
2016-04-28 English
Declaration of Voting Results & Voting Rights Announcements 2016
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'DGAP Voting Rights Announcement' and contains sections like 'Notification of Major Holdings', detailing the acquisition/disposal of shares with voting rights, the date the threshold was crossed (22 Apr 2016), and the resulting percentage of voting rights (4.92%). This content directly corresponds to the definition of announcing changes in significant share ownership levels, which maps to the Major Shareholding Notification category (MRQ). Although the header mentions 'Voting Rights Announcements', the specific content structure aligns best with MRQ, which covers changes in holdings crossing thresholds, often reported via voting rights mechanisms like the German WpHG mentioned.
2016-04-27 English
STADA Arzneimittel AG: Successful refinancing through the securing of additional promissory note loans of a total of Euro 350 million
Capital/Financing Update Classification · 98% confidence The document is a press release announcing that STADA Arzneimittel AG has successfully secured additional promissory note loans totaling Euro 350 million to refinance existing debt. This action directly relates to the company's financing activities and capital structure management. Based on the provided definitions, this clearly falls under 'Capital/Financing Update' (Code: CAP). It is not an earnings release, an annual report, or a management discussion, but a specific announcement about debt placement and refinancing.
2016-04-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.